Clinical trials located in


Firenze city is located in Italy. Currently, 7 clinical trials are being conducted in this city.

  • CT-EU-00116638


    • ABP 206
    • Nivolumab
  • Study of KRT-232 Combined with Ruxolitinib for Myelofibrosis Patients

    This here clinical trial is looking at a new drug called KRT-232 that’s taken by mouth. The study aims to see if combining KRT-232 with the existing drug ruxolitinib can help folks with myelofibrosis who ain’t responding well enough to just taking ruxolitinib alone.

    The main goal in the first part of the study is to find the right dose of KRT-232 to use when combined with ruxolitinib. They’ll be looking closely at any side effects to make sure the dose is safe. In the second part, they’ll check if the combination of the two drugs can shrink the size of the spleen by at least 35% after 6 months of treatment.

    • KRT-232
    • Ruxolitinib
  • Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

    • placebo
    • Rosnilimab
  • Study on INCB000928 Alone or With Ruxolitinib for Anemia in Myeloproliferative Disorders

    This clinical trial is designed to explore the effects of a new medication called INCB000928, either on its own or when used together with another drug known as ruxolitinib. The main goal is to see how safe and tolerable this treatment is for individuals suffering from anemia due to certain myeloproliferative disorders, including conditions like post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis. These are types of blood disorders that can lead to symptoms such as fatigue due to anemia.

    The study is divided into two parts: the first part will focus on finding the right dose of the medication, and the second part will expand on these findings to further understand the treatment’s effects. Participants in this study will be closely monitored to assess any side effects and to see how well the treatment is working, with a particular focus on how it impacts anemia and the need for blood transfusions.

    This research is being conducted in an open-label which means both the researchers and participants will know which treatment is being administered. The safety, tolerability, and effectiveness of INCB000928, both as a standalone therapy and in combination with ruxolitinib, will be evaluated over approximately 13 months. This study represents an important step towards finding new treatments for those dealing with the challenges of anemia due to myeloproliferative disorders.

    • Ruxolitinib
    • INCB000928
  • Study on the Safety and Effectiveness of INCB057643 for Myelofibrosis and Other Myeloid Neoplasms

    This clinical trial is focused on evaluating the safety, tolerability, and initial effectiveness of a medication called INCB057643, either on its own or in combination with another drug known as ruxolitinib. It is designed for participants who are dealing with myelofibrosis or other advanced myeloid neoplasms, which are types of blood disorders. The study aims to understand how well participants can handle the treatment and to observe any potential benefits or side effects that may occur during the trial. The treatment’s impact will be measured by monitoring the number of treatment-related adverse events, which includes any new or worsening symptoms following the start of the medication. This study is an important step towards finding new treatment options for individuals with myelofibrosis and related conditions, offering hope for better management of these diseases.

    • INCB057643
    • Ruxolitinib
  • Study on Ravulizumab’s effect on Immunoglobulin A Nephropathy

    The study is looking into the effectiveness of a medication called ravulizumab for adults who have a kidney condition known as Immunoglobulin A Nephropathy (IgAN). This condition can lead to kidney damage over time, and the study aims to find out if ravulizumab can help reduce the amount of protein lost in urine—a common problem in IgAN—and slow down the decrease in kidney function.

    In this study, about 450 participants who are at a high risk of their disease getting worse will be chosen. These participants must have been on stable treatment for their IgAN for at least three months before the study starts. They will then receive either ravulizumab or a placebo, which is a treatment with no active drug, through an IV infusion based on their weight. The main goal is to see if those who receive ravulizumab have a significant improvement in their condition compared to those who receive the placebo.

    The study will have two main checkpoints. The first one, at Week 34, will check how much protein is in the urine, and the second one, at Week 106, will assess how well the kidneys are filtering waste from the blood. Additionally, a smaller group of participants with more advanced kidney issues will receive ravulizumab to further explore its effects.

    After the study ends at Week 106, participants will have the option to continue receiving ravulizumab in a follow-up period to see how long-term treatment affects their condition. This study is a chance for people with IgAN to potentially slow down their disease progression and improve their quality of life.

    • placebo
    • Ravulizumab
  • Discovering Biomarkers in Rett Syndrome: A Multicenter Observational Study

    The BIRS (Biomarkers in Rett Syndrome) study is a long-term, observational, multicenter research project focused on understanding Rett Syndrome (RTT) better. RTT is a severe neurological disorder that mainly affects females, showing symptoms like slowed head growth, walking and balance issues, repetitive hand movements, and loss of communication skills, among others. This study is crucial because it aims to find early biomarkers of RTT, which could help in diagnosing the condition sooner and improving treatment options.

    The research will be conducted across several Italian centers, including IRCCS Stella Maris, AOU Meyer, and Versilia Hospital. It’s designed to monitor patients over four years, collecting a wide range of data, from genetic information to detailed clinical observations. The study will also compare affected individuals with their siblings to identify any differences that could point to early signs of RTT.

    Participants will undergo annual follow-ups, including various tests like EEGs to record brain activity, brain MRIs, and bone densitometry, among others. The study also uses innovative tools like the Eye Tracker, specifically for RTT patients, to understand their condition better.

    Your privacy is a top priority in this study. All personal information will be kept confidential, with data stored securely and accessible only to authorized personnel. Before joining, you’ll receive a detailed explanation of the study and what’s involved, ensuring you’re fully informed.

    This research is not just about understanding RTT better but also about finding ways to improve the lives of those affected by it. If you or a loved one is dealing with RTT and are interested in contributing to this vital research, the BIRS study might be an opportunity to consider.

See more clinical trials in other cities in Italy: